ST-2; a Non-invasive Fibrosis Marker for Chronic Hepatitis B

Turkiye Yuksek Ihtisas Education and Research Hospital

Status: Unknown

Conditions: Sequela of Chronic Liver Disease

Study type: Observational

Funder types: Other

Identifiers

NCT01633554

IKalkan24190708 (Registry Identifier)

24190708

Details and patient eligibility

About

IL-33 is a recently identified number of the IL-1 family. Hepatic over-expression of IL-33 has been recently linked to liver fibrosis. ST-2 exerts pro-inflammatory effects of IL-33. We aimed to determine ability of ST2 to predict fibrosis in chronic hepatitis B.

Full description

ST-2 is an IL-1 receptor family member and exists in both a membrane-bound isoform and a soluble (sST2) isoform. It has a functional ligand (Interleukin-33) and via ST-2/IL-33 inflammation and immunity is regulated. Hepatic over-expression of IL-33 has been recently linked to liver fibrosis. ST-2 exerts pro-inflammatory effects of IL-33. We aimed to determine ability of ST2 to predict fibrosis in chronic hepatitis B.

Enrollment: 95 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Clinical diagnosis of chronic hepatitis B or liver cirrhosis

Exclusion criteria

• Accompanying chronic inflammatory disease

Trial design

95 participants in 3 patient groups

Chronic Hepatitis B Group

Description:

Patients with chronic hepatitis B

Cirrhosis

Description:

Patients with liver cirrhosis

Control Group

Description:

Control Group: Healthy Volunteers